Abstracts tagged "anti-TNF therapy"

Abstract Number: 933 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study
Bon San Koo¹, Ji Seon Oh ², Seo Young Park ³, Ga Young Ahn ⁴, Seunghun Lee ⁵, Kyung Bin Joo ⁶ and Tae-Hwan Kim ⁷, ¹Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ²Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea, Seoul, Republic of Korea, ³Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Korea University Guro Hospital, Seoul, Republic of Korea, ⁵Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁶Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: It is difficult to evaluate the role of TNF inhibitor therapy in slowing the radiologic progression in patients with ankylosing spondylitis (AS) because of…
Abstract Number: 1518 • 2019 ACR/ARP Annual Meeting
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases
Matthew Thomas ¹, Gavin Shaddick ², Rachel Charlton ¹, Charlotte Cavill ³, Richard Holland ⁴, Florenzo Iannone ⁵, Giovanni Lapadula ⁶, Simona Lapriore ⁵, Jakub Závada ⁷, Michal Uher ⁸, Karel Pavelka ⁹, Lenka Szczukova ¹⁰, Prodromos Sidiropolous ¹¹, Irini Flouri ¹¹, Burkhard Moeller ¹², Michael J. Nissen ¹³, Ruediger B. Mueller ¹⁴, Almut Scherer ¹⁵, Neil McHugh¹ and Alison Nightingale ¹, ¹University of Bath, Bath, United Kingdom, ²University of Exeter, Exeter, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵University of Bari, Bari, Italy, ⁶Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy., Bari, Italy, ⁷Institute of Rheumatology, Prague, Prague, Czech Republic, ⁸Institute of Health Information and Statistics of the Czech Republic, and Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ¹⁰Masaryk University, Brno, Czech Republic, ¹¹University of Crete, Crete, Greece, ¹²University Hospital Bern, Bern, Switzerland, ¹³University Hospital Geneva, Geneva, Switzerland, ¹⁴Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ¹⁵SCQM Foundation, Zürich, Switzerland
Background/Purpose: A large proportion of psoriatic arthritis (PsA) patients are prescribed a tumour necrosis factor inhibitor (TNFi) in combination with methotrexate (MTX), however the value…
Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Maya H. Buch¹, Bara Erhayiem², Graham Fent², Paul Baxter³, Elizabeth M.A. Hensor⁴, Adam McDiarmid², Peter Swoboda⁵, Ananth Kidambi², David Ripley², Pankaj Garg², Sarah Horton⁴, Raluca Bianca Dumitru⁴, Kamran Naraghi⁴, John Greenwood⁶, Paul Emery⁷, Sue Pavitt⁸ and Sven Plein², ¹Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, ²Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁸Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
Abstract Number: 1497 • 2018 ACR/ARHP Annual Meeting
PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors
Keith Johnson, Nancy Schoenbrunner and Dina Ghiassian, Scipher Medicine Inc, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism…
Abstract Number: 2888 • 2018 ACR/ARHP Annual Meeting
Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Borja Hernández-Breijo¹, Victoria Navarro-Compán¹, Ana Martínez¹, Andrea Jochems¹, Alejandro Villalba², Diana Peiteado³, Eva L. Kneepkens⁴, Gerrit Wolbink⁴, Theo Rispens⁵, Dora Pascual-Salcedo¹, Alejandro Balsa¹ and Chamaida Plasencia¹, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Reade, Amsterdam, Netherlands, ⁵Immunopathology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: In patients with axial spondyloarthritis (axSpA), the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate (MTX) and sulfasalazine (SSZ), as well…
Abstract Number: 1936 • 2018 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Piotr Wiland¹, Sławomir Jeka², Eva Dokoupilová^3,4, Juan Manuel Miranda Limón⁵, Julia Jauch-Lembach⁶, Anjali Thakur⁶, Halimuniyazi Haliduola⁶ and Norman B Gaylis⁷, ¹Wrocław Medical University, Wrocław, Poland, ²Collegium Medicum UMK, 2nd University Hospital, Bydgoszcz, Poland, ³MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic, ⁴Faculty of Pharmacy, University of Veterinary and Pharmaceutical sciences, Brno, Czech Republic, ⁵RM Pharma Specialists, Mexico City, Mexico, ⁶Hexal AG, Holzkirchen, Germany, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: GP2017, a proposed adalimumab biosimilar, matched reference adalimumab (refADL) in preclinical and pharmacokinetics studies.1,2 The confirmatory efficacy and safety study in patients with plaque-type…
Abstract Number: 2890 • 2018 ACR/ARHP Annual Meeting
Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
Jun Won Park¹, Min Jung Kim¹, Hyoun-Ah Kim², Kichul Shin³, Yong-Beom Park⁴, Yeong Wook Song⁵ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Although recent treatment guideline of axial spondyloarthritis (axSpA) by the European League Against Rheumatism (EULAR) recommended that tapering of tumor necrosis factor inhibitor (TNFi)…
Abstract Number: 2270 • 2018 ACR/ARHP Annual Meeting
Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Monica Calderón Goercke², Diana Prieto Peña², Rosalía Demetrio-Pablo³, Javier Loricera³, Eva Peña Sainz-Pardo³, M. Victoria Hernández⁴, Alfredo Adan⁵, Marina Mesquida⁵, Santos Insua⁶, Jose M Herreras⁷, Olga Maíz⁸, Ana Blanco⁹, Myriam Gandía¹⁰, David Diaz-Valle¹¹, Lucía Martínez-Costa¹², Elia Valls-Pascual¹², Gisela Díaz-Cordovés¹³, Manuel Díaz-Llopis¹⁴, Inmaculada Calvo¹⁵, Ignacio Torre-Salaberri¹⁶, Antonio Atanes¹⁷, Luis Francisco Linares¹⁸, Marisa Hernández¹⁹, Emma Beltrán²⁰, Miguel Cordero-Coma²¹, Elena Aurrecoechea²², Félix Francisco²³, Raquel Almodóvar González²⁴, Oscar Ruiz Moreno²⁵, Fernando Jiménez-Zorzo²⁶, Joan Miquel Nolla²⁷, Consuelo Modesto²⁸, Enar Pons¹, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ⁷Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ¹⁰Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ¹¹Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹²Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ¹³Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹⁴Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁵Hospital Universitario La Fe, Valencia, Spain, ¹⁶Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁷Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹⁸Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ²¹Ophthalmology, Hospital de León. Spain, León, Spain, ²²Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²³Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ²⁴Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ²⁵Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁶Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁸Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain
Background/Purpose: Cystoid macular edema (CME) is the main cause of irreversible visual loss in patients with uveitis. Our aim objective was to determine the efficacy…
Abstract Number: 63 • 2018 ACR/ARHP Annual Meeting
TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis
Emily Wu¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Interstitial lung disease (ILD) is a significant contributor to rheumatoid arthritis (RA) mortality, yet its pathogenesis remains enigmatic. One theory posits that initial inflammatory…
Abstract Number: 2429 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study
Laura Andreoli¹, Maria Chiara Gerardi², Chiara Bazzani³, Matteo Filippini³, Micaela Fredi², Roberto Gorla³, Maria Grazia Lazzaroni², Cecilia Nalli², Marco Taglietti³, Andrea Lojacono⁴, Sonia Zatti⁴, Mario Motta⁵ and Angela Tincani², ¹Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁴Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁵Neonatology and NICU, Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Treatment with tumor necrosis factors inhibitors (TNFi) during pregnancy may be required to control maternal disease which can be a threat for maternal-fetal well-being.…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 2557 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
Philip Helliwell¹, Dafna D Gladman², Soumya D Chakravarty³, Shelly Kafka⁴, Chetan S Karyekar⁴, Yin You⁵, Arthur Kavanaugh⁶ and Lianne S. Gensler⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK, Leeds, United Kingdom, ²Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: In PSUMMIT 1&2, Phase 3 trials of ustekinumab (UST) in adults w/ active psoriatic arthritis (PsA), 30.1% & 22.4% of patients (pts) had peripheral…
Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Robert B.M. Landewé¹, Désirée van der Heijde², Maxime Dougados³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Bengt Hoepken⁶, Karen Thomas⁶ and Lianne S. Gensler⁷, ¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, ⁴Ruhr-University Bochum, Herne, Germany, ⁵Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷University of California, San Francisco, CA
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].